MOUNTAIN VIEW, Calif., Jan. 24, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) today announced that a number of hospitals across North America have adopted the company's IV compounding technology to help enhance safety, improve therapy, reduce cost, and facilitate compliance in the IV room.
According to Pharmacy Purchasing & Products' State of Pharmacy Compounding 2017, 44 percent of healthcare facilities expect to see an increase in in-house compounding volumes over the next three years.1 The Institute for Safe Medication Practices (ISMP) recommends that organizations have a strategic plan for implementing sterile compounding technology.2 As the market leader in IV automation and support services, Omnicell's comprehensive suite of solutions helps facilities of varying scale take control of one of the most critical areas of pharmacy to drive improved care.3
"The challenge for any hospital pharmacy is identifying opportunities to improve processes to deliver the best care to patients," said Michael Campbell, PharmD, MBA, director of pharmacy, at Pomona Valley Hospital Medical Center. "By leveraging IV automation for sterile compounding, we can drive down costs and redirect those savings to support clinical care."
Pomona Valley is one of many health systems who have selected Omnicell IV automation compounding solutions and are scheduled to complete installations during 2018. Others include:
- Baptist Jacksonville, Jacksonville, FL
- Brigham and Women's Hospital, Boston, MA
- CoxHealth, Springfield, MO
- Hamilton Health Sciences, Ontario, Canada
- Infirmary Health, Mobile, AL
- Massachusetts General Hospital, Boston, MA
- Penn State Health Milton S. Hershey Medical Center, Hershey, PA
- University Healthcare System, Augusta, GA
- UPMC, Pittsburgh, PA
- Vancouver Island Health Authority, British Columbia, Canada
"Automating some or all of the IV compounding process enables hospitals to control the quality and cost of IV therapy," said Doug Descalzi, vice president and GM, IV Solutions at Omnicell. "As hospitals recognize the need to provide a higher level of clinical care to their patients, we're proud to offer solutions that not only improve the safety of medications within these facilities, but enable highly trained clinical staff to move away from more routine tasks and refocus on patient care."
Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.
Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.
Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.
Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.
For more information about Omnicell, Inc. please visit www.omnicell.com.
- All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
- All other brand or product names may be trademarks or registered trademarks of their respective companies.
1 Pharmacy Purchasing & Products, "State of Pharmacy Compounding 2017." (April 2017). https://www.pppmag.com/digitalmag/Main.php?MagNo=185&PageNo=1#page/1
3 KLAS Performance Report: IV Compounding 2017. ©2017 KLAS Enterprises, LLC. All rights reserved. www.KLASresearch.com.
SOURCE Omnicell, Inc.